Frankfurt - Delayed Quote • EUR Knight Therapeutics Inc. (04K.F) Follow Compare 3.7600 +0.0200 +(0.53%) At close: January 24 at 8:57:57 AM GMT+1 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 04K.F 1D 5D 3.30% 1M 8.67% 3M 0.53% 6M 0.53% YTD 7.43% 1Y -1.57% 5Y -31.01% All -1.70% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: 04K.F View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Knight Therapeutics Inc. (TSE:GUD) most popular amongst individual investors who own 41% of the shares, institutions hold 24% Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD) Knight Therapeutics (TSE:GUD) investors are sitting on a loss of 33% if they invested five years ago Knight Therapeutics Inc (KHTRF) Q3 2024 Earnings Call Highlights: Revenue Growth Amidst Margin ... Knight Therapeutics Reports Third Quarter 2024 Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico Knight Therapeutics Inc (KHTRF) Q2 2024 Earnings Call Highlights: Record Revenues and Strategic ... Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies Related Tickers 4521.T Kaken Pharmaceutical Co., Ltd. 4,315.00 +0.54% SUPN Supernus Pharmaceuticals, Inc. 38.55 -0.23% PCRX Pacira BioSciences, Inc. 24.52 +5.10% PRFX PainReform Ltd. 3.5700 +11.91%